Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure‐related causes after cancer therapy

Abstract

AimsTo describe the characteristics and time to death of patients with breast or haematological cancer who died of heart failure (HF) after cancer therapy. Patients with an index admission for HF who died of HF‐related causes (IAHF) and those with no index admission for HF who died of HF‐related causes (NIAHF) were compared.Methods and resultsWe performed a linked data analysis of cancer registry, death registry, and hospital administration records (n = 15 987). Index HF admission must have occurred after cancer diagnosis. Of the 4894 patients who were deceased (30.6% of cohort), 734 died of HF‐related causes (50.1% female) of which 279 (38.0%) had at least one IAHF (41.9% female) post‐cancer diagnosis. Median age was 71 years [interquartile range (IQR) 62–78] for IAHF and 66 years (IQR 56–74) for NIAHF. There were fewer chemotherapy separations for IAHF patients (median = 4, IQR 2–9) compared with NIAHF patients (median = 6, IQR 2–12). Of the IAHF patients, 71% had died within 1 year of the index HF admission. There was no significant difference in HF‐related mortality in IAHF patients compared with NIAHF (HR, 1.10, 95% CI, 0.94–1.29, P = 0.225).ConclusionsThe profile of IAHF patients who died of HF‐related causes after cancer treatment matched the current profile of HF in the general population (over half were aged ≥70 years). However, NIAHF were younger (62% were aged ≤69 years), female patients with breast cancer that died of HF‐related causes before hospital admission for HF‐related causes—a group that may have been undiagnosed or undertreated until death.

Cardiotoxicity after cancer treatment: a process map of the patient treatment journey

“…The time from cancer diagnosis to cardiotoxicity in this cohort was between 0 and 18 years with mean time to death of 5 years for 16 patients. Mortality from cardiotoxicity has been demonstrated to be higher than both cancer and CVD alone [36].…”

Modern‐day cardio‐oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’

“…In patients with HF, many different co‐morbidities can influence the patients' burden of disease . Common co‐morbidities in patients with HF include iron deficiency, anaemia, liver dysfunction, chronic kidney disease, central sleep apnoea, chronic obstructive pulmonary disease, sexual dysfunction, cachexia, sarcopenia, anorexia, and also cancer . Professor Rudolf De Boer from Groningen, the Netherlands, presented several studies, which have shown that cancer patients have an increased risk to develop HF and that patients with both, cancer and HF, demonstrate even worse prognosis than both diseases alone .…”

Updates in heart failure: what last year brought to us

“…They seem more important in HFpEF and HFmrEF, whereas HFrEF patients have more often CAD as the main cause of HF . Co‐morbidities are usually divided into cardiovascular, such as hypertension, CAD, atrial fibrillation, stroke, and non‐cardiovascular, such as cancer, chronic renal dysfunction, obstructive lung disease, sleep apnoea, iron deficiency, anaemia, sarcopenia, anorexia, frailty, cachexia, liver dysfunction,diabetes mellitus, obesity, and psychiatric disorders . They are often associated with an increased risk of HF in initially asymptomatic patients as they may cause or favour the development of cardiac dysfunction.…”